Chemokine receptor 5 knockout strategies.

PubWeight™: 1.22‹?› | Rank: Top 10%

🔗 View Article (PMC 3066441)

Published in Curr Opin HIV AIDS on January 01, 2011

Authors

Paula Cannon1, Carl June

Author Affiliations

1: Molecular Microbiology & Immunology, University of Southern California Keck School of Medicine, Los Angeles, California, USA. pcannon@usc.edu

Associated clinical trials:

Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-728 for HIV (Zinc-Finger) | NCT00842634

Articles citing this

HIV prevention transformed: the new prevention research agenda. Lancet (2011) 4.23

Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs. Lancet (2013) 2.11

Precision editing of large animal genomes. Adv Genet (2012) 1.34

International AIDS Society global scientific strategy: towards an HIV cure 2016. Nat Med (2016) 1.29

Coupling endonucleases with DNA end-processing enzymes to drive gene disruption. Nat Methods (2012) 1.28

Novel cell and gene therapies for HIV. Cold Spring Harb Perspect Med (2012) 1.07

T-cell therapies for HIV. Immunotherapy (2013) 0.99

Pre-clinical modeling of CCR5 knockout in human hematopoietic stem cells by zinc finger nucleases using humanized mice. J Infect Dis (2013) 0.97

Combinatorial anti-HIV gene therapy: using a multipronged approach to reach beyond HAART. Gene Ther (2013) 0.93

Controlling the HIV/AIDS epidemic: current status and global challenges. Front Immunol (2012) 0.92

Targeted gene therapies: tools, applications, optimization. Crit Rev Biochem Mol Biol (2012) 0.91

Using defined finger-finger interfaces as units of assembly for constructing zinc-finger nucleases. Nucleic Acids Res (2013) 0.91

Homing endonucleases: from genetic anomalies to programmable genomic clippers. Methods Mol Biol (2014) 0.89

Lens epithelium-derived growth factor/p75 qualifies as a target for HIV gene therapy in the NSG mouse model. Mol Ther (2012) 0.88

LAHEDES: the LAGLIDADG homing endonuclease database and engineering server. Nucleic Acids Res (2012) 0.87

Receptor-mediated delivery of engineered nucleases for genome modification. Nucleic Acids Res (2013) 0.86

Preclinical safety and efficacy of an anti-HIV-1 lentiviral vector containing a short hairpin RNA to CCR5 and the C46 fusion inhibitor. Mol Ther Methods Clin Dev (2014) 0.85

State-of-the-art human gene therapy: part II. Gene therapy strategies and clinical applications. Discov Med (2014) 0.84

Efficient Modification of the CCR5 Locus in Primary Human T Cells With megaTAL Nuclease Establishes HIV-1 Resistance. Mol Ther Nucleic Acids (2016) 0.81

Functionally Active HIV-Specific T Cells that Target Gag and Nef Can Be Expanded from Virus-Naïve Donors and Target a Range of Viral Epitopes: Implications for a Cure Strategy after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant (2015) 0.80

The potential for genetically altered microglia to influence glioma treatment. CNS Neurol Disord Drug Targets (2013) 0.80

The clinical applications of genome editing in HIV. Blood (2016) 0.79

CCR5 expression is reduced in lymph nodes of HIV type 1-infected women, compared with men, but does not mediate sex-based differences in viral loads. J Infect Dis (2013) 0.78

Current translational and clinical practices in hematopoietic cell and gene therapy. Cytotherapy (2012) 0.77

Simultaneous screening and validation of effective zinc finger nucleases in yeast. PLoS One (2013) 0.77

Genome-Wide Association Study of Human Immunodeficiency Virus (HIV)-1 Coreceptor Usage in Treatment-Naive Patients from An AIDS Clinical Trials Group Study. Open Forum Infect Dis (2014) 0.76

Development of Lentiviral Vectors Simultaneously Expressing Multiple siRNAs Against CCR5, vif and tat/rev Genes for an HIV-1 Gene Therapy Approach. Mol Ther Nucleic Acids (2016) 0.76

T-cell therapies for HIV: Preclinical successes and current clinical strategies. Cytotherapy (2016) 0.75

In Vivo Delivery Systems for Therapeutic Genome Editing. Int J Mol Sci (2016) 0.75

CD4(+) T Cells Modified by the Endoribonuclease MazF Are Safe and Can Persist in SHIV-infected Rhesus Macaques. Mol Ther Nucleic Acids (2014) 0.75

Novel AIDS therapies based on gene editing. Cell Mol Life Sci (2017) 0.75

Articles cited by this

Genome editing with engineered zinc finger nucleases. Nat Rev Genet (2010) 18.88

Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature (1996) 15.91

Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. Nat Biotechnol (2008) 14.75

Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med (2009) 11.68

CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature (1996) 11.37

Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery. Nat Biotechnol (2007) 9.23

Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo. Nat Biotechnol (2010) 6.55

The lifetime cost of current human immunodeficiency virus care in the United States. Med Care (2006) 5.87

T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice. Cell (2008) 4.32

Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. Ann Intern Med (2000) 3.95

Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. Lancet (2004) 3.59

RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma. Sci Transl Med (2010) 3.53

A highly efficient short hairpin RNA potently down-regulates CCR5 expression in systemic lymphoid organs in the hu-BLT mouse model. Blood (2009) 2.25

RNAi-mediated CCR5 silencing by LFA-1-targeted nanoparticles prevents HIV infection in BLT mice. Mol Ther (2009) 1.55

Novel humanized murine models for HIV research. Curr HIV/AIDS Rep (2009) 1.40

T-cell protection and enrichment through lentiviral CCR5 intrabody gene delivery. Gene Ther (2006) 1.38

Phase 2a study of the CCR5 monoclonal antibody PRO 140 administered intravenously to HIV-infected adults. Antimicrob Agents Chemother (2010) 1.16

Two-year safety and virologic efficacy of maraviroc in treatment-experienced patients with CCR5-tropic HIV-1 infection: 96-week combined analysis of MOTIVATE 1 and 2. J Acquir Immune Defic Syndr (2010) 1.14

Generation of HIV-1-specific CD8+ cell responses following allogeneic hematopoietic cell transplantation. Blood (2008) 1.10

Inhibition of HIV-1 infection by a unique short hairpin RNA to chemokine receptor 5 delivered into macrophages through hematopoietic progenitor cell transduction. J Gene Med (2010) 1.02

A comprehensive definition of the major antibody specificities in polyclonal rabbit antithymocyte globulin. Transplantation (1994) 1.00

First case of successful allogeneic stem cell transplantation in an HIV-patient who acquired severe aplastic anemia. Haematologica (2007) 0.96

Failure of bone marrow transplantation to eradicate HIV reservoir despite efficient HAART. AIDS (2007) 0.94

Specific transduction of HIV-susceptible cells for CCR5 knockdown and resistance to HIV infection: a novel method for targeted gene therapy and intracellular immunization. J Acquir Immune Defic Syndr (2009) 0.91

CCR5 antagonists: host-targeted antiviral agents for the treatment of HIV infection, 4 years on. Antivir Chem Chemother (2010) 0.90

Decreased HIV diversity after allogeneic stem cell transplantation of an HIV-1 infected patient: a case report. Virol J (2010) 0.81

Impact of Delta 32-CCR5 heterozygosity on HIV-1 genetic evolution and variability--a study of 4 individuals infected with closely related HIV-1 strains. Virology (2008) 0.80

Interventions for body habitus changes associated with HIV infection and its treatment. Curr HIV/AIDS Rep (2007) 0.78